Emisphere Technologies, Inc. to Hold Conference Call to Discuss Second Quarter 2006 Financial Results

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Emisphere Technologies, Inc. to Hold Conference Call to Discuss Second Quarter 2006 Financial Results

    TARRYTOWN, N.Y., Aug. 1 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its
second quarter 2006 financial results on Tuesday, August 8, 2006, beginning
at 10:00 a.m. Eastern Time. A replay of the call will be accessible
approximately three hours following the end of the call and will be
archived through August 15, 2006.
    The live conference call dial-in number is: 1-877-704-5391 (U.S./Canada)
                                                1-913-312-1301 (International)

    The live conference call ID number is:      9124489

    To access a replay of the call:             1-888-203-1112 (U.S./Canada)
                                                1-719-457-0820 (International)

    Conference replay PIN number is:            9124489
    Emisphere will simultaneously be webcasting this teleconference. To
access the live broadcast in listen-only mode or the subsequently archived
recording, please go to the Investor Relations portion of the Company's
website at:
    http://www.emisphere.com/ir.asp
    Please visit the site at least five minutes prior to start time for
instructions.
    About Emisphere Technologies, Inc.
    Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit the Company website,
http://www.emisphere.com.

SOURCE Emisphere Technologies, Inc.

http://www.emisphere.com

http://www.emisphere.com/ir.asp
CONTACT:
Stewart Siskind of Emisphere Technologies,
Inc., +1-914-785-4742; or Dan Budwick of BMC Communications,
+1-212-477-9007 ext. 14, for Emisphere Technologies, Inc.